QUESTIONSLate Phase Drug Development World Americas 2011
Venue: Hyatt Regency
Location: Boston, Massachusetts, United States
| Event Date/Time: Mar 22, 2011 | End Date/Time: Mar 25, 2011 |
| Early Registration Date: Feb 11, 2011 |
Report as SpamDescription
Health Network has shaped a programme which provides the best speakers to give real solutions to the key strategic and operational challenges of late phase activity. The whole agenda is built so that you get the most out of it with every presentation followed by a Q&A session. This is a forum to grow your business with abundant networking opportunities during the drink reception, lunch and workshops.
This meeting provides an extensive and diverse agenda, giving you everything you need to know about late phase. You will hear from industry thought leaders from an impressive list of companies including: AstraZeneca, Pfizer, GSK, Merck, Abbott, Eli Lilly & Co, Novartis, EMD Serono, Endo, Takeda, Lundbeck, Genzyme, Eisai, Biogen Idec, Genentech and Blue Cross Blue Shield who will provide you with the best possible advice on how to improve performance in late phase research.
Key issues to be addressed:
• Strategic challenges in late phase trials – how can we structure the late phase apparatus and turn insight from the real world into a competitive commercial asset?
• Pipeline lifecycle management – R&D which can be built from a real world feedback loop?
• Planning for phase IIIb/IV – building cost-effective non interventional studies using multi-trial sites in a real world setting
• Analyzing and interpreting observational studies – how do you effectively collect, validate and analyze observational data
• Patient registries – an invaluable resource, how do they contribute to late phase development?
• What are the considerations of Comparative Effectiveness Research in informed healthcare decision making?
• How can benefit/risk management demonstrate consistency in product value, both for regulators and payers?
• How is product reimbursement linked in a healthcare system undergoing real reform and can we differentiate our drugs from competitors in the eyes of the payer?
• How do you gain market authorisation globally based on late phase data?
This meeting provides an extensive and diverse agenda, giving you everything you need to know about late phase. You will hear from industry thought leaders from an impressive list of companies including: AstraZeneca, Pfizer, GSK, Merck, Abbott, Eli Lilly & Co, Novartis, EMD Serono, Endo, Takeda, Lundbeck, Genzyme, Eisai, Biogen Idec, Genentech and Blue Cross Blue Shield who will provide you with the best possible advice on how to improve performance in late phase research.
Key issues to be addressed:
• Strategic challenges in late phase trials – how can we structure the late phase apparatus and turn insight from the real world into a competitive commercial asset?
• Pipeline lifecycle management – R&D which can be built from a real world feedback loop?
• Planning for phase IIIb/IV – building cost-effective non interventional studies using multi-trial sites in a real world setting
• Analyzing and interpreting observational studies – how do you effectively collect, validate and analyze observational data
• Patient registries – an invaluable resource, how do they contribute to late phase development?
• What are the considerations of Comparative Effectiveness Research in informed healthcare decision making?
• How can benefit/risk management demonstrate consistency in product value, both for regulators and payers?
• How is product reimbursement linked in a healthcare system undergoing real reform and can we differentiate our drugs from competitors in the eyes of the payer?
• How do you gain market authorisation globally based on late phase data?
Venue
Additional Information
To view the conference agenda in full and for further information please download the brochure: http://www.terrapinn.com/template/live/documents.aspx?e=4023
